Nuvation Bio Inc (NUVB) Stock Forecast & Price Target
Nuvation Bio Inc · NYSE
$6.66+0.24 (+3.74%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Nuvation Bio Inc, 7 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $7.00 to $19.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $12.38 sits 86% above the current $6.66. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy788%
Hold113%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Nuvation Bio Inc.
As of Jul, 7 of 8 firms rate NUVB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NUVB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.11 – $-0.11 · 1 analysts · -21% YoY
Next period, 1 analysts expect Nuvation Bio Inc to earn $-0.11 a share (range $-0.11 – $-0.11), versus $-0.14 a year earlier. Full-year consensus is $-0.28, growing to $-0.06 the year after.
REVENUE · NEXT QUARTER
$39.2M
Range $29.3M – $43.9M · 1 analysts · +198% YoY
Revenue is expected to reach $39.2M (range $29.3M – $43.9M), +198.4% year-over-year. Full-year consensus is $202.9M, rising to $289.9M next year.
Top analysts covering Nuvation Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NUVB.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$12.00+80.2% to target
Overall win rate
53%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$10.00+50.2% to target
Overall win rate
50%
+ Follow
#3
Leonid Timashev
RBC Capital · Rank #69
Buy
$19.00+185.3% to target
Overall win rate
42%
+ Follow
#4
David Nierengarten
Wedbush · Rank #115
Buy
$11.00+65.2% to target
Overall win rate
41%
+ Follow
#5
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$17.00+155.3% to target
Overall win rate
38%
+ Follow
NUVB stock forecast FAQ
What is NUVB's average 12-month price target?+
The 8 analysts with a live target average $12.38 for Nuvation Bio Inc over the next 12 months, ranging from a $19.00 high to a $7.00 low.
Is NUVB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NUVB?+
The Street-high target is $19.00 (RBC Capital), and the Street-low is $7.00 (UBS). The average of all 8 active targets is $12.38.
How many Wall Street analysts cover NUVB?+
8 analysts have an active rating on Nuvation Bio Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering NUVB?+
Among analysts who currently cover NUVB, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $12.00 target.
What is Nuvation Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.11 – $-0.11) across 1 analysts. Full-year EPS is projected at $-0.28, rising to $-0.06 the following year.
How much revenue is Nuvation Bio Inc expected to report next quarter?+
Consensus revenue is $39.2M (range $29.3M – $43.9M). Full-year revenue is projected at $202.9M, growing to $289.9M next year.
Have analysts been upgrading or downgrading NUVB lately?+
As of Jul, 7 of 8 firms rate NUVB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NUVB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
